In this manuscript, we review abnormal RIP1/RIP3/MLKL pathway activation and the mechanisms of action during the pathogenesis of lung diseases in children and provide new ideas for the prevention and treatment of NEC in children with lung diseases. This evidence concerns the gene MLKL and lung disorder.